New insider Abbvie Inc. claimed ownership of 7,048 shares (SEC Form 3)
$ABBV
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 07/01/2025 |
3. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common stock, $0.01 par value | 7,048(1) | D | |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Option (Right to buy)(2) | (2) | 02/14/2034 | Common Stock | 5,043 | $175.28 | D | |
| Option (Right to buy)(3) | (3) | 02/12/2035 | Common Stock | 4,687 | $192.86 | D | |
| Explanation of Responses: |
| 1. Includes 1,113 restricted stock units granted under the AbbVie Amended and Restated 2013 Incentive Stock Program. These restricted stock units vest in full on February 16, 2026, and include the right to have stock withheld for tax purposes. |
| 2. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 1,681 shares on 2/15/2025, and will become exercisable as to 1,681 shares on 2/15/2026 and as to 1,681 shares on 2/16/2027. |
| 3. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 1,563 shares on 2/13/2026, as to 1,562 shares on 2/13/2027 and as to 1,562 shares on 2/13/2028. |
| Remarks: |
| This initial holding statement has been made for Demetris D. Crum using the Issuer's CIK codes in order to satisfy Form 3 filing requirements for newly appointed company officers. An amendment will be filed for Mr. Crum upon receipt of his CIK filer codes from the SEC. Exhibit 24 - Power of Attorney. |
| /s/ T.O. Odutayo, Attorney-in-Fact for Demetris D. Crum | 07/11/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||